Cambridge, Mass.-based Blueprint Medicines Corp.’s price tag and label for Ayvakit (avapritinib) caused some chagrin on Wall Street as observers continued to weigh the drug’s odds against ripretinib, the competing drug for which Deciphera Pharmaceuticals Inc. awaits regulatory action.
BEIJING – China-U.S. biotech Transcenta Holding Ltd., headquartered in Shanghai and Boston, completed a series B+ financing round to secure $100 million to continue its efforts in developing oncology and bone disorder drugs and to prepare for an IPO.
NBE Therapeutics AG raised $22 million in a series C round to take its first antibody-drug conjugate (ADC), NBE-002, into the clinic. NBE-002, which targets receptor tyrosine kinase-like orphan receptor 1 (ROR1), is in development for both solid tumors and lymphomas
HONG KONG – South Korean-based med-tech Lunit Inc., of Seoul, has secured ₩30 billion (US$25.6 million) in series C funding. Founded in 2013, the Korean company has raised $50 million so far. Lunit’s corporate value was evaluated at as much as ₩200 billion as of the fundraising.
RSS
